Literature DB >> 16530513

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid.

Albert Parés1, Llorenç Caballería, Juan Rodés.   

Abstract

BACKGROUND & AIMS: Because the efficacy of UDCA on long-term outcome of primary biliary cirrhosis (PBC) has not been completely elucidated, we have assessed the course and survival of patients with PBC treated with UDCA and compared with the survival predicted by the Mayo model and the estimated survival of a standardized population.
METHODS: (One hundred ninety-two patients [181 women] with PBC treated with UDCA [15 mg/kg per day] for 1.5-14 years.) Response to treatment was defined by an alkaline phosphatase decrease greater than 40% of baseline values or normal levels after 1 year of treatment. The predicted survival was obtained by the Mayo model and the estimated survival was taken from the standardized matched Spanish population.
RESULTS: Seventeen patients died or fulfilled criteria for liver transplantation (8.9%). The observed survival was higher than that predicted by the Mayo model and lower than that of the control population (P < .001). One hundred seventeen patients (61%) responded to treatment. The survival of responders was significantly higher than that predicted by the Mayo model and similar to that estimated for the control population (P = .15). By contrast, the survival of patients without biochemical response was lower than that estimated for the Spanish population (P < .001) although higher than that predicted by the Mayo model.
CONCLUSIONS: Biochemical response to UDCA after 1 year is associated with a similar survival to the matched control population, clearly supporting the favorable effects of this treatment in PBC. The suboptimal survival of nonresponders identifies the group for further treatments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530513     DOI: 10.1053/j.gastro.2005.12.029

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  170 in total

Review 1.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

Review 2.  Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature.

Authors:  Nicola Bizzaro; Giovanni Covini; Floriano Rosina; Paolo Muratori; Elio Tonutti; Danilo Villalta; Fiorenza Pesente; Maria Grazia Alessio; Marilina Tampoia; Antonio Antico; Stefan Platzgummer; Brunetta Porcelli; Lucia Terzuoli; Marco Liguori; Danila Bassetti; Ignazio Brusca; Piero L Almasio; Giuseppe Tarantino; Chiara Bonaguri; Paolo Agostinis; Elena Bredi; Renato Tozzoli; Pietro Invernizzi; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

3.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

Review 4.  New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.

Authors:  James L Boyer
Journal:  J Hepatol       Date:  2006-12-18       Impact factor: 25.083

5.  Von Willebrand factor and alkaline phosphatase predict re-transplantation-free survival after the first liver transplantation.

Authors:  Andreas Wannhoff; Conrad Rauber; Kilian Friedrich; Christian Rupp; Wolfgang Stremmel; Karl Heinz Weiss; Peter Schemmer; Daniel N Gotthardt
Journal:  United European Gastroenterol J       Date:  2016-07-08       Impact factor: 4.623

6.  Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis.

Authors:  L M Stinton; M Swain; R P Myers; A A Shaheen; M J Fritzler
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

7.  38-year-old woman with abnormal liver enzymes and hyperlipidemia.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Mayo Clin Proc       Date:  2009-06       Impact factor: 7.616

Review 8.  [Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults].

Authors:  S Hohenester; U Beuers
Journal:  Internist (Berl)       Date:  2017-08       Impact factor: 0.743

9.  Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis.

Authors:  Takeji Umemura; Satoru Joshita; Tomohiro Sekiguchi; Yoko Usami; Soichiro Shibata; Takefumi Kimura; Michiharu Komatsu; Akihiro Matsumoto; Masao Ota; Eiji Tanaka
Journal:  Am J Gastroenterol       Date:  2015-04-28       Impact factor: 10.864

10.  MiR-139-5p is associated with inflammatory regulation through c-FOS suppression, and contributes to the progression of primary biliary cholangitis.

Authors:  Tomohiro Katsumi; Masashi Ninomiya; Taketo Nishina; Kei Mizuno; Kyoko Tomita; Hiroaki Haga; Kazuo Okumoto; Takafumi Saito; Tooru Shimosegawa; Yoshiyuki Ueno
Journal:  Lab Invest       Date:  2016-09-26       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.